AVDL Avadel Pharmaceuticals Plc

Price (delayed)

$7.85

Market cap

$459.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$543.62M

Highlights
AVDL's quick ratio has surged by 53% since the previous quarter
Avadel Pharmaceuticals's net income has plunged by 179% from the previous quarter but it has soared by 74% YoY
Avadel Pharmaceuticals's EPS has shrunk by 169% QoQ but it has surged by 84% YoY
The gross profit has shrunk by 84% YoY and by 59% QoQ
The revenue has plunged by 82% YoY and by 55% from the previous quarter

Key stats

What are the main financial stats of AVDL
Market
Shares outstanding
58.49M
Market cap
$459.13M
Enterprise value
$543.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.36
Price to sales (P/S)
45.46
EV/EBIT
558.13
EV/EBITDA
224.08
EV/Sales
53.87
Earnings
Revenue
$10.09M
EBIT
$974,000
EBITDA
$2.43M
Free cash flow
-$60.64M
Per share
EPS
-$0.09
Free cash flow per share
-$1.04
Book value per share
$2.33
Revenue per share
$0.17
TBVPS
$4.72
Balance sheet
Total assets
$292.94M
Total liabilities
$156.44M
Debt
$143.66M
Equity
$136.5M
Working capital
$233.19M
Liquidity
Debt to equity
1.05
Current ratio
26.57
Quick ratio
22.48
Net debt/EBITDA
34.83
Margins
EBITDA margin
24%
Gross margin
67.4%
Net margin
-55%
Operating margin
-16.4%
Efficiency
Return on assets
-1.7%
Return on equity
-3.4%
Return on invested capital
0.3%
Return on capital employed
0.3%
Return on sales
9.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVDL stock price

How has the Avadel Pharmaceuticals stock price performed over time
Intraday
0%
1 week
2.21%
1 month
6.8%
1 year
-10.49%
YTD
17.51%
QTD
-13.16%

Financial performance

How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$10.09M
Gross profit
$6.81M
Operating income
-$1.65M
Net income
-$5.55M
Gross margin
67.4%
Net margin
-55%
Avadel Pharmaceuticals's net income has plunged by 179% from the previous quarter but it has soared by 74% YoY
AVDL's operating margin has shrunk by 140% QoQ but it has soared by 58% YoY
The company's operating income has shrunk by 118% QoQ but it has surged by 92% YoY
The gross profit has shrunk by 84% YoY and by 59% QoQ

Growth

What is Avadel Pharmaceuticals's growth rate over time

Valuation

What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.36
P/S
45.46
EV/EBIT
558.13
EV/EBITDA
224.08
EV/Sales
53.87
Avadel Pharmaceuticals's EPS has shrunk by 169% QoQ but it has surged by 84% YoY
The stock's price to book (P/B) is 55% less than its 5-year quarterly average of 7.4 but 29% more than its last 4 quarters average of 2.6
The company's equity fell by 16% QoQ
The price to sales (P/S) is 110% higher than the last 4 quarters average of 21.6
The revenue has plunged by 82% YoY and by 55% from the previous quarter

Efficiency

How efficient is Avadel Pharmaceuticals business performance
AVDL's return on assets has dropped by 171% since the previous quarter but it has surged by 86% year-on-year
The ROE has plunged by 167% from the previous quarter
Avadel Pharmaceuticals's return on sales has surged by 123% YoY but it has shrunk by 73% QoQ
The ROIC has soared by 103% YoY but it has plunged by 88% from the previous quarter

Dividends

What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVDL.

Financial health

How did Avadel Pharmaceuticals financials performed over time
The total assets is 87% more than the total liabilities
AVDL's quick ratio has surged by 53% since the previous quarter
Avadel Pharmaceuticals's current ratio has soared by 52% from the previous quarter
The debt is 5% greater than the equity
Avadel Pharmaceuticals's debt to equity has plunged by 73% YoY but it has increased by 31% from the previous quarter
The company's equity fell by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.